Cytomegalovirus infection/disease after hematopoietic stem cell transplantation

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) disease has historically been a main cause of death after allogeneic hematopoietic stem cell transplantation (HSCT). Since the introduction of prophylactic or preemptive therapy against CMV, the incidence of CMV disease has been successfully reduced. However, breakthrough CMV disease, particularly CMV gastrointestinal disease, remains one of the major infectious complications. Administration of an antiviral agent, ganciclovir, is often associated with myelotoxicity in HSCT recipients, and delayed immune reconstitution against CMV. Delayed immune reconstitution is a possible cause of the increasing incidence of late (more than 3 months after transplant) CMV disease after HSCT in this era of preemptive therapy. Foscarnet and valganciclovir are the available alternatives to intravenous ganciclovir. Foscarnet is not myelotoxic and has a toxicity profile different from ganciclovir. Valganciclovir, a prodrug of ganciclovir, has a higher bioavailability than oral ganciclovir and could be of clinical use, particularly in the outpatient setting or for patients requiring long-term antiviral therapy. Recent technological developments have enabled the visualization and isolation of CMV-specific T cells. Using these techniques, an individualized approach could be conducted based on each patient's immune reconstitution against CMV. In this review, we summarize the recent progress and current knowledge of CMV infection and disease after allogeneic HSCT.

Original languageEnglish
Pages (from-to)588-595
Number of pages8
JournalInternational Journal of Hematology
Volume91
Issue number4
DOIs
Publication statusPublished - 2010 May

Fingerprint

Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Cytomegalovirus
Ganciclovir
Foscarnet
Antiviral Agents
Gastrointestinal Diseases
Incidence
Prodrugs
Biological Availability
Cause of Death
Outpatients
Therapeutics
T-Lymphocytes
Transplants

Keywords

  • CMV antigenemia
  • Cytomegalovirus
  • Foscarnet
  • Ganciclovir
  • Hematopoietic stem cell transplantation
  • Immunotherapy
  • Preemptive therapy
  • Prophylactic therapy
  • Real-time PCR

ASJC Scopus subject areas

  • Hematology

Cite this

Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. / Mori, Takehiko; Kato, Jun.

In: International Journal of Hematology, Vol. 91, No. 4, 05.2010, p. 588-595.

Research output: Contribution to journalArticle

@article{e78d8d3a667e4361af827a58d2ae401c,
title = "Cytomegalovirus infection/disease after hematopoietic stem cell transplantation",
abstract = "Cytomegalovirus (CMV) disease has historically been a main cause of death after allogeneic hematopoietic stem cell transplantation (HSCT). Since the introduction of prophylactic or preemptive therapy against CMV, the incidence of CMV disease has been successfully reduced. However, breakthrough CMV disease, particularly CMV gastrointestinal disease, remains one of the major infectious complications. Administration of an antiviral agent, ganciclovir, is often associated with myelotoxicity in HSCT recipients, and delayed immune reconstitution against CMV. Delayed immune reconstitution is a possible cause of the increasing incidence of late (more than 3 months after transplant) CMV disease after HSCT in this era of preemptive therapy. Foscarnet and valganciclovir are the available alternatives to intravenous ganciclovir. Foscarnet is not myelotoxic and has a toxicity profile different from ganciclovir. Valganciclovir, a prodrug of ganciclovir, has a higher bioavailability than oral ganciclovir and could be of clinical use, particularly in the outpatient setting or for patients requiring long-term antiviral therapy. Recent technological developments have enabled the visualization and isolation of CMV-specific T cells. Using these techniques, an individualized approach could be conducted based on each patient's immune reconstitution against CMV. In this review, we summarize the recent progress and current knowledge of CMV infection and disease after allogeneic HSCT.",
keywords = "CMV antigenemia, Cytomegalovirus, Foscarnet, Ganciclovir, Hematopoietic stem cell transplantation, Immunotherapy, Preemptive therapy, Prophylactic therapy, Real-time PCR",
author = "Takehiko Mori and Jun Kato",
year = "2010",
month = "5",
doi = "10.1007/s12185-010-0569-x",
language = "English",
volume = "91",
pages = "588--595",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Cytomegalovirus infection/disease after hematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Kato, Jun

PY - 2010/5

Y1 - 2010/5

N2 - Cytomegalovirus (CMV) disease has historically been a main cause of death after allogeneic hematopoietic stem cell transplantation (HSCT). Since the introduction of prophylactic or preemptive therapy against CMV, the incidence of CMV disease has been successfully reduced. However, breakthrough CMV disease, particularly CMV gastrointestinal disease, remains one of the major infectious complications. Administration of an antiviral agent, ganciclovir, is often associated with myelotoxicity in HSCT recipients, and delayed immune reconstitution against CMV. Delayed immune reconstitution is a possible cause of the increasing incidence of late (more than 3 months after transplant) CMV disease after HSCT in this era of preemptive therapy. Foscarnet and valganciclovir are the available alternatives to intravenous ganciclovir. Foscarnet is not myelotoxic and has a toxicity profile different from ganciclovir. Valganciclovir, a prodrug of ganciclovir, has a higher bioavailability than oral ganciclovir and could be of clinical use, particularly in the outpatient setting or for patients requiring long-term antiviral therapy. Recent technological developments have enabled the visualization and isolation of CMV-specific T cells. Using these techniques, an individualized approach could be conducted based on each patient's immune reconstitution against CMV. In this review, we summarize the recent progress and current knowledge of CMV infection and disease after allogeneic HSCT.

AB - Cytomegalovirus (CMV) disease has historically been a main cause of death after allogeneic hematopoietic stem cell transplantation (HSCT). Since the introduction of prophylactic or preemptive therapy against CMV, the incidence of CMV disease has been successfully reduced. However, breakthrough CMV disease, particularly CMV gastrointestinal disease, remains one of the major infectious complications. Administration of an antiviral agent, ganciclovir, is often associated with myelotoxicity in HSCT recipients, and delayed immune reconstitution against CMV. Delayed immune reconstitution is a possible cause of the increasing incidence of late (more than 3 months after transplant) CMV disease after HSCT in this era of preemptive therapy. Foscarnet and valganciclovir are the available alternatives to intravenous ganciclovir. Foscarnet is not myelotoxic and has a toxicity profile different from ganciclovir. Valganciclovir, a prodrug of ganciclovir, has a higher bioavailability than oral ganciclovir and could be of clinical use, particularly in the outpatient setting or for patients requiring long-term antiviral therapy. Recent technological developments have enabled the visualization and isolation of CMV-specific T cells. Using these techniques, an individualized approach could be conducted based on each patient's immune reconstitution against CMV. In this review, we summarize the recent progress and current knowledge of CMV infection and disease after allogeneic HSCT.

KW - CMV antigenemia

KW - Cytomegalovirus

KW - Foscarnet

KW - Ganciclovir

KW - Hematopoietic stem cell transplantation

KW - Immunotherapy

KW - Preemptive therapy

KW - Prophylactic therapy

KW - Real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=77954541853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954541853&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0569-x

DO - 10.1007/s12185-010-0569-x

M3 - Article

C2 - 20414753

AN - SCOPUS:77954541853

VL - 91

SP - 588

EP - 595

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -